Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma
Table 2
Baseline data and patient characteristics.
AA (n=59)
Non-AA (n=59)
p-value
Age (median)
67.21
64.4
p=0.372
Gender
Male
23
32
p=0.140
Female
36
27
Comorbidities
Hypertension
46
31
p=0.0064
Diabetes Mellitus
18
11
p=0.1991
Human Immunodeficiency Virus
1
0
p=1
Hepatitis C Virus
1
0
p=1
Systemic Lupus Erythematosus
1
1
p=1
Congestive Heart Failure
10
8
p=0.799
Chronic Kidney Disease
9
6
p=0.582
Laboratory Data (median)
Hemoglobin (g/dL)
9
10.6
p<0.001
Platelets (109/L)
194
206
p=0.126
eGFR (MDRD, mL/min/1.73 m2)
47.89
51.95
p=0.522
Myeloma Parameters (median)
Protein Gap (g/dL)
5.9
4.15
p=0.00241
Lactate Dehydrogenase (U/L)
216
182.5
p=0.400
Beta2-Microglobulin (mg/L)
5.15
4.98
p=0.742
Urine Protein (mg/24 hrs)
279.5
1218
p=0.192
Serum Free Light Chain Ratio (Involved/Uninvolved)
70.37
164.96
p=0.103
M-protein (g/dL)
3.2
2
p=0.0139
% Bone Marrow Plasmacytosis
50
40
p=0.053
Light Chain only
12
13
p=0.841
Adverse Risk Cytogenetics
12
14
P=0.825
Concurrent Amyloid
4
2
p=0.679
R-ISS Stage
1
4
10
p=0.153
2
35
39
p=0.568
3
20
10
p=0.056
Criteria for Treatment
Hypercalcemia (Calcium > 11 mg/dL)
13
13
p=1
eGFR <60 mL/min/1.73 m2
45
37
p=0.161
eGFR 60-90 mL/min/1.73 m2
14
22
Anemia (Hemoglobin < 10 g/dL)
32
17
p=0.0086
Bone disease
31
29
p=0.854
Therapy Received
Triplet
24
27
p=0.71
Doublet
31
31
p=1
Other
4
1
p=0.364
Bortezomib-based
50
50
p=1
Bortezomib/Dexamethasone
24
23
p=0.884
Bortezomib/Lenalidomide/Dexamethasone
12
17
p=0.353
Cyclophosphamide/Bortezomib/Dexamethasone
11
6
p=0.225
Other
3
4
p=0.705
Bisphosphonate
47
52
p=0.317
Includes deletion 17p, t(4;14), t(14;20), t(14;16), and/or 1q21 gain. Triplet = 3-drug combination consisting of a corticosteroid and 2 other antimyeloma therapies. Doublet = 2-drug combination consisting of a corticosteroid and another antimyeloma agent.
